4th Annual Alzheimer's Drug Development Summit

According to the Alzheimer’s Association, by 2030, it is estimated 1 out of 8 people over age 65 will have Alzheimer’s and nearly 50% of those over 85 will be affected.

According to the Alzheimer’s Association, by 2030, it is estimated 1 out of 8 people over age 65 will have Alzheimer’s and nearly 50% of those over 85 will be affected.  Now, more than ever, it is critical for researchers, industry drug developers and regulators to work together in order to bring disease modifying therapies for AD to market.  According to a study performed by the University of Connecticut, the successful development of disease modifying drugs for Alzheimer’s could potentially save the U.S. Healthcare system an estimated $4.0 trillion dollars.  CBI’s Annual Alzheimer’s Drug Development Summit brings together key researchers and stakeholders to examine the latest disease modifying therapies and pre-symptomatic approaches for the treatment of Alzheimer’s Disease.

Topics being discussed in 2010 include:

Assess the latest clinical data on drug candidates from Pfizer, Allon Therapeutics and EnVivo Pharmaceuticals

Review the f